Dr. Reddy’s Laboratories
RDY – Dr. Reddys Announces the Launch of Gemcitabine for Injection
Wednesday, July 27th, 2011Dr. Reddy’s Q1 FY12 Financial Results
Wednesday, July 20th, 2011Key Highlights Consolidated revenues are at Rs. 19.7 billion ($444 million) in Q1 FY12 versus Rs. 16.8 billion ($377 million) in Q1 FY11, year-on-year growth of 18%. Revenues from Global Generics for Q1 FY12 are at Rs. 14.4 billion ($323 million). Year-on-year growth of 21% mainly driven by North America generics and Russia. Revenues from [...]
Dr. Reddy’s Laboratories
Wednesday, June 1st, 2011Dr. Reddy’s Laboratories is an integrated pharmaceutical company and operates in business segments such as global generics, active ingredients and proprietary products. Dr Reddy’s March quarter results were higher-than-estimated with revenue growing 22.8% year-over-year, driven by robust growth of 67.6% in U.S. generics and 25.7% in Russia and CIS. The launch of generic fexofenadine pseudoephedrine [...]
Dr Reddy’s says U.S. court clears generic Allegra sale
Wednesday, February 2nd, 2011“This is a positive for the company. Since Dr Reddy’s is the only player for this product, it should be able to do decent sales,” Sarabjit Kour Nangra, vice president of research and who tracks the sector at Angel Broking said. Dr. Reddy’s Laboratories announced today that on Friday, 28 January 2011, the U.S. District [...]
Dr Reddy’s Laboratories will start to see the benefits from its tie-up with GlaxoSmithKline in two or three years
Wednesday, February 2nd, 2011“Overall, it is a good relationship that is working well and going as predicted, but the financial impact is going to be seen only two to three years from now,” he told Reuters on the sidelines of the annual meeting of the World Economic Forum. “It takes time to develop the products and register them [...]
Dr. Reddy’s Laboratories Ltd. (RDY) Q3 2011 Earnings Call
Wednesday, January 26th, 2011The financial highlights are as follows. Consolidated revenues for the quarter are at $424 million and represent a year-on-year growth of 10% and a sequential growth of 2%. Revenues from our Global Generics business stand at $303 million for the quarter, representing a year-on-year growth of 16%. Revenues from the Pharmaceutical Services and Active Ingredients [...]
Dr Reddy’s profit hurt by German unit, shares fall
Wednesday, January 26th, 2011Dr Reddy’s Laboratories, India’s No. 2 drugmaker, swung to a profit in the third quarter but missed analysts’ estimates as sales at its German unit plunged. Sales in Europe, one of Dr Reddy’s largest markets, fell 18 percent, driven by a 33-percent drop in Germany, as its German unit Betapharm struggled with pricing pressure amid [...]
Biosimilars – The Next Generic Honeypot
Tuesday, September 14th, 2010Generic drugs are certainly a significant part of the landscape in the healthcare world. Not only do they save healthcare consumers (and their insurance companies) millions of dollars a year, but they are a thriving industry in their own right. Companies like India’s Dr. Reddy’s Laboratories (NYSE:RDY) and its nearly ten-fold larger rival Teva Pharmaceuticals [...]
Dr Reddy’s forecasts low single digit revenue growth in FY10
Wednesday, January 20th, 2010Chief Executive G.V. Prasad said the company expected to post a “low single digit” revenue growth in the fiscal year that ends in March, down from its previous forecast of a 10-percent growth over the previous year. “Our German business has contracted beyond our expectations and there is a little bit of slowdown in the [...]
Dr Reddy’s posts $113 mln net loss in Q3
Wednesday, January 20th, 2010Indian drug maker Dr Reddy’s Laboratories Ltd posted a 5.2 billion rupees consolidated loss ($113 million) in the December quarter, compared with a profit of 2.4 billion rupees in the year-ago period, missing forecasts. Dr Reddy’s, India’s second-biggest drug maker by sales, said in September it had voluntarily recalled four products from its key U.S. [...]
Dr. Reddy’s (RDY) Downgrade from Hold to Sell – Analyst rating from Deutsche Bank
Tuesday, January 19th, 2010Dr. Reddy’s downgraded by Deutsche Bank
Tuesday, January 19th, 2010Transgene Biotek Sells Obesity Drug Technology License To Dr Reddy’s
Thursday, January 7th, 2010Transgene Biotek Ltd. said Thursday it has sold the license for the manufacturing process of obesity drug orlistat to Dr. Reddy’s Laboratories Ltd.